Tepezza, more commonly referred to by its brand name Teprotumumab, is a medication approved to treat thyroid eye disease (TED), an eye condition characterized by eye protrusion, swelling, inflammation and other related symptoms that manifest themselves visually. Tepezza specifically targets these issues and has been FDA approved as an aid in decreasing eye protrusion while alleviating other associated symptoms associated with TED.
Reported adverse events of Tepezza include muscle spasms, nausea and vomiting, hair loss (alopecia), diarrhea, fatigue, high blood sugar levels, dry skin problems (dysgeusia) as well as headaches; however the primary focus of litigation regarding Tepezza involves its potential association with hearing loss, tinnitus and other ear conditions.
The Tepezza lawsuit encompasses claims from individuals who have experienced hearing loss, tinnitus or ear damage after taking Tepezza. Lawsuits were filed against Horizon Pharmaceuticals as the manufacturer, alleging they failed to provide sufficient warning of these possible side effects and should inform patients and healthcare providers about them before prescribing Tepezza.
If you have suffered hearing loss after using Tepezza, or experienced any other adverse side effects due to treatment with Horizon Pharmaceuticals' product, you may be eligible to join ongoing litigation against Horizon. A personal injury attorney specializing in pharmaceutical litigation should evaluate your case and help assess eligibility for compensation - they can guide you through the legal process and inform you about your rights.
At this stage, it is hard to predict exactly what may occur in terms of specific outcomes or settlements for Tepezza lawsuits. Much will depend on evidence presented in court regarding whether Horizon Pharmaceuticals knew about the risk associated with Tepezza and acted negligently, among other considerations. It may lead to settlements where Horizon Pharmaceuticals agrees to pay a sum in order to end cases without going to trial; however, until further steps are taken by litigation it remains uncertain how this unfolds exactly.